Abstract:Objective To investigate the clinical features of patients with primary central nervous system lymphoma (PCNSL), to analyze and evaluate relevant prognostic factors and therapeutic regimens. Methods The retrospective study was conducted on 64 cases with PCNSL. The Log-rank test was applied to univariate analyses, whereas Cox regression was used in multivariate analyses on pertinent data of survival. Results The retrospective study was done on 64 newly diagnosed PCNSL cases. The median age was 54.9 years old, and the overall male/female ratio was >1. Most of tumors (40/64) presented solely; 54% (33/61) of all tumors were associated to deep lesions. Twenty-six patients with integrate analyzable data were diagnosed and treated at our hospital, among which, 19 patients received chemotherapy alone; 1 patient received WBRT alone, and 6 received WBRT first, and chemotherapy one month later. The median survival time of all patients was 17 months. Statistically significant predictors shown in the univariate analyses were anemia degree and the use of HD-MTX and teniposide. Moderate to severe anemia alone was a significant predictor of bad prognosis, whereas chemotherapeutic regimens without HD-MTX and teniposide also showed bad prognosis. A combination of radiotherapy and chemotherapy had substantially improved their prognosis (X 2 =3.24, P =0.07). Age, gender, physical status and tumor location had not statistically significant on prognosis; CHOP regimen, rituximab, intrathecal injection of chemotherapeutic drug had non-significant impact on prognosis and survival. Cox-regression analysis for multivariate analyses on survival data showed the HD-MTX treatment was independent favorable predictor of prognosis; however, location and numbers of intracranial lesions, combination of radio and chemotherapy did not have independent prognostic impact on prognosis. Conclusion Prognosis of patients with PCNSL is extremely poor; HD-MTX or teniposide improve the prognosis and survival of patients. Prognosis of patients with moderate to severe anemia is even worse.

Pediatric primary central nervous system lymphoma

Primary central nervous system lymphoma mimicking recurrent depressive disorder: A case report.

Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.

Study on primary central nervous system lymphoma in pediatric patients

Advances in the Diagnosis of Primary Central Nervous System Lymphoma

Advances in the Diagnosis and Treatment of Primary Central Nervous System Lymphoma

Advances in relevant prognostic factors of primary central nervous system lymphoma

The Molecular Landscape of Primary CNS Lymphomas (PCNSLs) in Children and Young Adults

Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features

Successful Treatment of Primary Central Nervous System Lymphoma without Irradiation in Children: Single Center Experience

Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases

A Retrospective Study of 40 Cases of Pathologically Established Primary Central Nervous System Lymphoma

The Clinical Features and Survival Analysis of Primary Central Nervous System Lymphoma

Cell-Block cytology in diagnosis of primary central nervous system lymphoma

Primary central nervous system lymphoma: a series report and literature review

Primary Central Nervous System Burkitt Lymphoma with Non-Immunoglobulin Heavy Chain Translocation in Right Ventricle: Case Report.

Current and emerging therapies for primary central nervous system lymphoma

Clinical features analysis on primary central nervous system lymphoma

Atypical B‐cell infiltrate in a pediatric patient: diagnostic and pathogenetic considerations

Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review

Novel Therapies for Primary Central Nervous System Lymphomas